Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
Open Access
- 3 January 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (1) , e0168947
Abstract
Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly difficult in recent years due to the variety of treatment options available and challenge deciding on the most appropriate treatment strategy for an individual patient. To facilitate the treatment strategy decision, disease assessment should involve molecular response to initial treatment for an individual patient. Patients predicted not to achieve major molecular response (MMR) at 24 months to frontline imatinib may be better treated with alternative frontline therapies, such as nilotinib or dasatinib. The aims of this study were to i) understand the clinical prediction ‘rules’ for predicting MMR at 24 months for CML patients treated with imatinib using clinical, molecular, and cell count observations (predictive factors collected at diagnosis and categorised based on available knowledge) and ii) develop a predictive model for CML treatment management. This predictive model was developed, based on CML patients undergoing imatinib therapy enrolled in the TIDEL II clinical trial with an experimentally identified achieving MMR group and non-achieving MMR group, by addressing the challenge as a machine learning problem. The recommended model was validated externally using an independent data set from King Faisal Specialist Hospital and Research Centre, Saudi Arabia. The common prognostic scores yielded similar sensitivity performance in testing and validation datasets and are therefore good predictors of the positive group. The G-mean and F-score values in our models outperformed the common prognostic scores in testing and validation datasets and are therefore good predictors for both the positive and negative groups. Furthermore, a high PPV above 65% indicated that our models are appropriate for making decisions at diagnosis and pre-therapy. Study limitations include that prior knowledge may change based on varying expert opinions; hence, representing the category boundaries of each predictive factor could dramatically change performance of the models.Keywords
Funding Information
- King Abdulaziz University of Saudi Arabia
- Novartis Pharma
This publication has 36 references indexed in Scilit:
- Biomarkers for determining the prognosis in chronic myelogenous leukemiaJournal of Hematology & Oncology, 2013
- EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experienceBlood, 2012
- Predicting the outcome of renal transplantationJournal of the American Medical Informatics Association, 2012
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreBlood, 2011
- Predicting response in CMLBlood, 2011
- Feature Subset Selection Problem using Wrapper Approach in Supervised LearningInternational Journal of Computer Applications, 2010
- Prognostic versus predictive value of biomarkers in oncologyEuropean Journal of Cancer, 2008
- Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemiaThe Lancet Oncology, 2007
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2006
- Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemiaBlood Reviews, 2006